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Introduction
Since first human infection with the highly pathogenic influenza virus (HPAI; H5N1) during an outbreak in Hong Kong at 1997, HPAI spread from Asia to Europe and Africa [1] . In 2014, natural infection of HPAI (H5N8) virus containing clade 2.3.4.4 hemagglu tinin (HA) have been reported in dogs in South Korea and this virus has been detected in many other countries in Asia and Europe now [2] . During the H5N8 outbreak, two different strains of H5N8 virus which showed highly sequence similarity were isolated from 38 wild birds. H5N8 viruses damaged to more than 200 poultry farms and decre ased significant egg production by 60% [3] . Although HPAI (H5N8) has not yet been found to cause disease in humans, there are some subtypes of HPAI such as H5N1, H7N9, and H5N6, which have caused severe illness or death in people. Recently studies show ed that vaccines for H5N1 showed crossreactivity against H5N8 virus [46] but vaccine containing H5N8 viral antigens has not been reported yet.
In general, influenza vaccine was produced in fertilized egg [7] . However, eggbased vaccine production has some limitations such as low productivity of HPAI vaccine and requirement of sealed facilities [8] . To overcome these, a new type of vaccine against influenza, made with viruslike particles (VLPs), has been purposed. Influenza VLPs which are synthesized in cells and released from cells look very like influenza virions. In previous studies, VLPs induced effective immune response more than subunit vaccine composed with recombinant pro tein antigens [912] . Recently, mammalian cell expression sys tems have been used for production of VLPs and followed by concentration with size exclusion filtration [10] . In this study, we produced influenza H5N8 VLPs for the first time using baculovirusinsect cell expressed system and applied nitro cellulose membrane-based filtration system (NCFS) for con centration of VLP as a vaccine candidate and evaluated yield property and immunogenicity.
Materials and Methods

Plasmid and cloning
H5N8 virus (A/mallard/Korea/W452/2014) derived HA and neuraminidase (NA) gene were generated by polymerase chain reaction (PCR) amplification following each primer: forward BamHIHA 5´AGC GGA TCC ATG GAG AAA ATA GTG CTT CTT3´, reverse XhoIHA 5´AGC CTC GAG TTA GAT GCA AAT TCT GCA TTG3´, forward BamHINA 5´AGC GGA TCC ATG AAT CCA AAT CAG AAA ATA G3´, reverse XhoINA 5´ AGC CTC GAG TTA CAT CTT ATC GAT GTC AAA3´. HA and NA gene were cloned into pFastBac1 plasmid between Bam-HI and XhoI. Influenza A/Puerto Rico/8/34 virus (PR8) de rived M1 gene was generated by reverse transcriptase poly merase chain reaction and PCR with following primers: for ward XbaIM1 5´AGG TCT AGA ATG AGT CTT CTA ACC GAG GT3´ and reverse XhoIM1 5´AGG CTC GAG TCA CTT GAA CCG TTG CAT C3´. M1 gene was cloned into pFastBac1 be tween XbaI and XhoI. For generation recombinant bacmid, recombinant pFastBac1 were transformed to DH10Bac.
Production of VLPs
Influenza H5N8 VLPs were produced as previously described [13] . Briefly, to generate recombinant baculovirus (rBV) ex pressing HA, NA, and M1 protein, bacmid encoding HA, NA, and M1 gene were transfected with Spodoptera frugiperda (Sf9) cells by lipofectamin agent (Invitrogen, Carlsbad, CA, USA). HA, NA, and M1 expressed rBV were coinfected with Sf9 cells at a 0.51 multiplicity of infection and infected cells were maintained in SF900II medium at 27°C. Day 3 postin fection, culture supernatants were harvested by centrifuga tion at 4,000 rpm for 15 minutes. Culture supernatants were concentrated by nitrocellulose membrane ultrafiltration sys tem using stirred cell (Amicon, Darmstadt, Germany). Super natant was filled in cell and gave pressure to cell by N2 gas.
Through the membrane with 100 kDa molecular weight cut off, components in culture supernatants less than 100 kDa were filtrated. VLPs in concentrated culture supernatants were purified by ultracentrifugation and performed by 20% and 60% sucrose gradient layer at 30,000 rpm for 1 hour at 4°C. HA titer of each production step were determined by HA assay as previously described [13] . Briefly, serially diluted samples were prepared in 96well Vbottom plate with phos phatebuffered saline (PBS) buffer and followed by addition of 0.5% chicken red blood cells at 4°C for 30 minutes.
Characterization of VLPs
Protein concentrations of VLPs were measured by bicincho ninic acid assay kit (Pirece, Rockford, IL, USA). Expression of HA, NA, and M1 in VLPs were determined by western blot analysis, VLPs were separated by 12% polyacrylamide gel and were transferred onto polyvinylidene difluoride membrane. Expression of HA, NA, and M1 were detected by H5N8 virus immunized mice serum or mouse antiinfluenza M1 IgG, fol lowed by detection goat antimouse IgG horseradish peroxi dase (HRP). For negative staining, VLPs were adsorbed on a Formvarcarbon coated EM grid for 1 minute and stained with 2% uranyl acetate for 15 seconds. VLPs were observed by transmission electron microscopy (JEM1011, JEOL, To kyo, Japan).
Mice immunization
For animal experiment, six week old of female BALB/c mice (n=6) were immunized intramuscularly with 100 µL of PBS buffer containing 10 µg H5N8 VLPs or immunized intrana sally with 30 µL of PBS buffer containing 10 µg H5N8 VLPs. Mice were received twice vaccination at 3 weeks apart. Post 3week prime or boost vaccination, serum samples were col lected by retroorbital bleeding.
Antibody response
Influenza specific antibody responses in immunized sera were determined by enzymelinked immunosorbent assay (ELISA) assay as previously described. Briefly, 96well plates were coated with 100 µL of coating buffer containing H5N8 inactivated virus at 4°C overnight. Plates were blacked with 200 µL of 3 % bovine serum albumin solution at 37°C for 1.5 hours. Immunized serum were diluted with PBS buffer and added to wells and incubated at 37°C for 1. mouse IgA at 37°C for 1 hour and then substrate tetramethyl benzidine solution was used to develop. The optical density was measured at wavelength 450 nm.
Results
Production of influenza VLPs
Influenza VLPs expressing HA and NA derived from HPAI (H5N8) were produced by baculovirusinsect cell expression system and concentrated by NCFS ultrafiltration (Fig. 1) . In step 1 purification, insect cell culture supernatant coinfected with rBV expressing HA, NA, and M1 influenza proteins were clarified by low speed centrifugation. Total HA activity was about 64,000 hemagglutinating unit (HAU) in 200 mL of clari fied insect cell culture supernatant (Table 1 ). In step 2, clari fied cell culture supernatant were put into the stirred cell de vices for NCFS and pressurized by N2 gas to force fluid through the nitrocellulose mem brane while retaining and concentrat ing the VLPs (Fig. 2A) . The stirred cell used gentle magnetic stirring to control the accumulation of VLPs on the membrane surface under high pressure about 55 psi at room temperature. Fig. 1 . Strategy of influenza virus like particles (VLPs) production using nitrocellulose membrane-based filtration system (NCFS). Influenza VLPs were generated by baculovirus-insect cell expression system and purified by NCFS and ultracentrifugation. HA, hemagglutinin; NA, neuraminidase.
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VLP purification
Co-infection with rBVs in sf9 insect cells Step HA titer (HAU/50 μL) Step Total HA Step HAU/μg NCFS was achieved with solution about 10fold concentra tion and yielding 80% based on total HA (Table 1) . Purity of HA antigen in concentrated solution by NCFS was increased to 6 fold higher than cell culture supernatant based on unit HA titer (Table 1) . Finally, VLP solution was purified by ultra centrifugation with 20% and 60% sucrose gradient (Fig. 2B ) with 64% recovery yield ( Table 1, Fig. 3B ). HA titer and unit HA activity in VLP solution were significantly increased dur ing purification process (Fig. 3A, C) . As a result, use these NCFS with stirred cell device was effective method to con centrate, diafilter and purify macromolecules such as VLP vaccines.
In vitro characterization of influenza VLPs
Expression of viral antigens in influenza VLPs were confirmed by western blotting analysis. Viral components in influenza VLPs were separated by sodium dodecyl sulfate polyacryl amide gel electrophoresis and detected by immunesera col lected from mice immunized with inactivated H5N8 influen za virus (Fig. 4A ) and monoclonal antiM1 antibody (Fig. 4B) . HA and M1 proteins were observed in size of 70 and 25 kDa, respectively (Fig. 4A, B) . Morphology of influenza VLPs were examined by transmission electron microscopy (Fig. 4C) . In fluenza VLPs which purified NCFS were identified as nanopar ticle with diameter of 80 nm which similar size with influenza virus particles. Therefore, those result indicated that VLPs con tained H5N8 influenza viral antigens were effectively produced by baculovirusinsect cell expression system and purified by NCFS with structural similarity. 
Humoral immune response induced by influenza VLPs
Influenza VLP vaccines were introduced into group of mice via intramuscular injection or intranasal route twice in three weeks interval (Table 2) . Three weeks after boost immuniza tion, mice sera were collected and measured influenza spe cific antibody responses by ELISA. Both intramuscular and intranasal immunization-induced significant level of virus specific IgG responses (Fig. 5A) . Systemic IgG responses in immunized sera were increase following boost vaccination but secretory IgA responses were not detected in blood even in intranasal immunization (Fig. 5B) . Those results indicated that H5N8 influenza VLPs purified by NCFS induced signifi cant level of virusspecific humoral immune responses.
Discussion
In 2014, highly pathogenic influenza A virus (H5N8) was iden tified in South Korea and widely spread to other country and continent including Asia and Europe. A potential spread of the virus was assumed via the migratory bird routes of duck, geese and swans [3, 1416] . Although the risk of human infec tion with HPAI H5N8 is considered very low, vaccine for pre vention of HPAI H5N8 should be prepared because it contin ues to evolve into many genetic lineages and clades. In previ ously studies, VLP vaccines containing HA and NA derived from H5N1 strain (A/meerkat/Shanghai/SH1/2012) were showed partial protective immune response against A/MD/ Korea/W452/14 H5N8 virus [17] but no any specific VLP vac cines against HPAI H5N8. In this study, we prepared H5N8 VLP vaccine using baculovirusinsect cell expression system. Usually, handling of cell culture medium with large scale is common technical problem during the VLP vaccine manu facturing process. To overcome this, we introduced the NCFS. Estimated size of H5N8 VLP is at least larger than 300 kDa due to their complex compositions such as viral proteins and in sect cell membrane. So, VLPs could be concentrated by size exclusion filtration using NCFS stirred cell without significant loss of antigen. After concentration, culture supernatant vol ume was decrease and HA titer was increased. When we com pared total HA unit before and after ultrafiltration with NCFS stirred cell in step 2, HA activity was preserved as approximate ly 80% and unit HA activity in 1 µg total protein was 6fold in creased. These results were indicated that size exclusion fil tration was effective method to concentration VLPs. Finally in step 3, HA titer was increased more than 30 times in compar ison with step 1. Total HA unit was preserved as approximate ly 64% and HA activity in 1 µg total protein was 170 fold incre ased. These results indicated that VLPs were concentrated and purified successfully by NCFS and sucrose gradient ul trafiltration. Moreover, H5N8 VLPs vaccine induced signifi cant level of IgG antibody both intramuscular and intranasal immunization in mice even after prime vaccination. These results indicated that VLP prepared by NCFS conserved their immunogenicity against antigen. We conclude that these VLP preparation method using nitrocellulose membrane filtration system represent a feasible strategy for VLP vaccine manufac turing.
